Rick Malley retweeted
Honored to be on a panel of distinguished academic med leaders/peds ID docs at the @PIDSociety @StJude meeting where we got to opine on the next 40 yrs of peds ID: consensus was we need more advocacy for the field and kids, and the opportunities are vast #luckytobePedsID
Rick Malley retweeted
9th Edition of Remington & Klein's Infectious Diseases of the Fetus & Newborn Infant to be published June 4th!
42 chapters, 1150 pages, 89 contributors
Thanks to my co-editor-in-chief Bonnie Maldonado and our associate editors Elizabeth Barnett, Kathy Edwards, and Rick Malley!
Rick Malley retweeted
Back from the 2023 @BostonChildrens Computational Health Informatics Program @bos_chip faculty retreat. Still absorbing the fantastic discussion and scientific debates. And spectacular keynotes by @stephen_wolfram @raykurzweil @rickmalley
Rick Malley retweeted
Don’t call Donald Trump’s Foreign Policy one of restraint.
My latest for @TheNatlInterest
nationalinterest.org/feature…
Rick Malley retweeted
Yesterday we announced the completion of the acquisition of @Affinivax – including access to the exciting MAPS technology. Check this out to learn more 👇
Rick Malley retweeted
New post on competing view of obesity cause and effect
@Medium
#CarbInsulinModel
davidludwigmd.medium.com/whe…
Rick Malley retweeted
What parents should know about the #monkeypox. Our Dr. Rick Malley @rickmalley answers your questions on @GMA. gma.abc/3oP7SWP
Targeted Transcriptomic Screen of Pneumococcal Genes Expressed during Murine and Human Infection | Infection and Immunity journals.asm.org/doi/10.1128…
Rick Malley retweeted
We're pleased to share the publication of data in the journal “Vaccines.” The article highlights foundational viral vaccine POC for our MAPS™ vaccine technology platform.
mdpi.com/2076-393X/10/7/1069
Rick Malley retweeted
Looking forward to helping @UCDavisMed @UCDavisHealth achieve greater, coordinated global collaboration, along with our other great schools @UCDavisGlobal @ucdavisvetmed @ucdavisAgFood @UCDavis_PHSEDU and so many more! So much need for coordinated global efforts and health!
Congratulations to our chair @nkuppermann for his new role as the Associate Dean for Global Health at @UCDavisMed!
Dr. Kuppermann will bring decades of experience and leadership in global health to the position and we are excited to see him in this role.
Rick Malley retweeted
Happy #PrideMonth! We celebrate Pride on this anniversary of the Stonewall Riots by reflecting on LGBTQIA+ history and striving towards greater visibility and equality. Support this community and the #NextGen Leaders here: pointfoundation.org/donate/ #PrideDay
Rick Malley retweeted
We are delighted to share this publication in the journal Vaccine, detailing results from the Phase 2 clinical trial of our lead novel vaccine candidate targeting Streptococcus pneumoniae, which was developed using our proprietary MAPS™ platform. sciencedirect.com/science/ar…
Rick Malley retweeted
At #ISPPD12, our poster presentation highlights the possibilities of engineering next generation pneumococcal vaccines. #MAPSnextgenvaccines affinivax.com/affinivax-pres…
Rick Malley retweeted
Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine at the 12th International Symposium on Pneumococci and Pneumococcal Diseases affinivax.com/affinivax-pres…
Rick Malley retweeted
Happy #Juneteenth2022! We take part in honoring this shared history which commemorates the anniversary of the news of freedom reaching enslaved Black Americans. We reflect on its significance and take stock of where we are still in the fight for equality. boston.gov/departments/small…
Rick Malley retweeted
It’s an exciting time at Affinivax and we are focused on the steadfast growth and opportunity within our Manufacturing department. Check out these open roles! affinivax.com/careers/ #WereHiring #SimplePowerfulVaccines
Rick Malley retweeted
New study led by CCDD alum @JosephLewnard with current CCDD director @mlipsitch and postdoc @rebeccajk13 in their @CDCgov capacities
Comparison of #SARS-CoV-2 infections shows reduced severity of Omicron infections compared to Delta and no differential risk of severe outcomes between subvariants BA.1 & BA.2, highlighting the importance of continual assessment of outcomes @UCBerkeleySPH
nature.com/articles/s41591-0…





























